ESC 2019 | CONDI-2ERIC-PPCI: Final Blow Against Ischemic Pre-Conditioning in Primary Angioplasty

Remote ischemic conditioning does not offer any clinical benefit to patients with ST-segment elevation acute myocardial infarction undergoing primary angioplasty, according to this study presented on Sunday at the European Society of Cardiology Congress 2019.

Prior studies were limited and small, but this analysis seems to provide definitive evidence with regard to ischemic pre-conditioning. The way to improve must be found somewhere else.

The study randomized 5401 patients with ST-segment elevation acute myocardial infarction undergoing primary angioplasty to remote ischemic pre-conditioning (either in the ambulance or on hospital admission) or not. The pre-conditioning procedure was performed intermittently through four cycles of 5-minute inflation of a blood-pressure cuff.


Read also: ESC 2019 | THEMIS-PCI: Unlike in the Main Study, Here Ticagrelor Is Indeed Effective.


After 1 year of follow-up, there were no differences between the control and active groups regarding the primary endpoint of cardiac death or heart failure readmission. There were also no differences in the secondary endpoints (a composite of cardiac death and heart failure readmission at 30 days, and major adverse cardiac or cerebrovascular events [MACCE] at 30 days and 1 year).

Results were consistent across subgroups (by age, diabetes status, infarct location, final TIMI flow, and time elapsed from first medical contact to balloon inflation).

Other forms of ischemic pre-conditioning, such as pharmacologic compounds (exenatide and cyclosporin) or mechanical postconditioning and balloon reinflation in the coronary artery, have also failed.

Original Title: Effect of remote ischaemic conditioning on clinical outcomes in patients with STEMI undergoing primary PCI: the CONDI-2/ERIC-PPCI trial.

Reference: Botker HE. Presentado el 1 de septiembre en el ESC 2019. Paris, Francia.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....